Vitamin d derivative shows promise in tough pancreatic cancer trial
NCT ID NCT04054362
First seen Nov 21, 2025 · Last updated May 12, 2026 · Updated 23 times
Summary
This study tested whether adding a drug called paricalcitol (similar to vitamin D) to standard chemotherapy could help people with advanced pancreatic cancer that had stopped responding to initial treatment. 27 adults with metastatic pancreatic cancer took part. The goal was to see if the addition improved disease control or symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Health NHS Trust
London, London, Greater, EC1M 6BQ, United Kingdom
Conditions
Explore the condition pages connected to this study.